Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC)

被引：0
|
作者：
Zarba, Martin
Ferrier, Evan
Wells, Connor
El Zarif, Talal
Basappa, Naveen S.
Ebrahimi, Hedyeh
Mckay, Rana R.
Wood, Lori
Beuselinck, Benoit
Suarez, Cristina
Takemura, Kosuke
Lalani, Aly-Khan A.
Li, Haoran
Spain, Lavinia Anne
Templeton, Arnoud J.
Powles, Thomas
Bjarnason, Georg A.
de Velasco, Guillermo
Choueiri, Toni K.
Heng, Daniel Yick Chin
机构：
[1] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada
[2] Tom Baker Canc Clin, Calgary, AB, Canada
[3] Barts Canc Inst, London, England
[4] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[5] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada
[6] City Hope Comprehens Canc Ctr, Duarte, CA USA
[7] Univ Calif San Diego, La Jolla, CA USA
[8] Dalhousie Univ, Queen Elizabeth II Hlth Sci Ctr, Halifax, NS, Canada
[9] UZ Leuven, Leuven, Belgium
[10] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Med Oncol, Barcelona, Spain
[11] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[12] McMaster Univ, Hamilton, ON, Canada
[13] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[14] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[15] St Clara Hosp, Basel, Switzerland
[16] Queen Mary Univ London, Barts Canc Inst, London, England
[17] Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[18] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
[19] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4514
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium
    Chittoria, Namita
    Zhu, Hui
    Choueiri, Toni K.
    Kroeger, Nils
    Lee, Jae-Lyun
    Srinivas, Sandy
    Knox, Jennifer
    Bjarnason, Georg A.
    MacKenzie, Mary J.
    Wood, Lori
    Vaishamayan, Ulka N.
    Agarwal, Neeraj
    Pal, Sumanta Kumar
    Tan, Min-Han
    Rha, Sun Young
    Yuasa, Takeshi
    Donskov, Frede
    North, Scott A.
    Rini, Brian I.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Stukalin, Igor
    Wells, J. Connor
    Graham, Jeffrey
    Yuasa, Takeshi
    Beuselinck, Benoit
    Kollmannsberger, Christian K.
    Ernst, D. Scott
    Agarwal, Neeraj
    Le, Tri
    Donskov, Frede
    Hansen, Aaron Richard
    Bjarnason, Georg A.
    Srinivas, Sandy
    Wood, Lori
    Alva, Ajjai Shivaram
    Kanesvaran, Ravindran
    Fu, Simon Yuen Fai
    Davis, Ian D.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [23] Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.
    Savard, Marie-France
    Wells, J. Connor
    Graham, Jeffrey
    Steinharter, John A.
    McGregor, Bradley Alexander
    Donskov, Frede
    Bjarnason, Georg A.
    Vaishampayan, Ulka N.
    Hansen, Aaron Richard
    Iafolla, Marco Adelmo James
    Zanotti, Giovanni
    Huynh, Lynn
    Duh, Mei Sheng
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [24] Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo plus Ipi): Results from the International mRCC Database Consortium (IMDC).
    Lemelin, Audreylie
    Takemura, Kosuke
    Ernst, Matthew Scott
    Wells, J. Connor
    Donskov, Frede
    Porta, Camillo
    de Velasco, Guillermo
    Davis, Ian D.
    Wood, Lori
    Pal, Sumanta Kumar
    Hansen, Aaron Richard
    Kollmannsberger, Christian K.
    Bjarnason, Georg A.
    Tran, Ben
    Li, Haoran
    Kanesvaran, Ravindran
    Powles, Thomas
    McKay, Rana R.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Additional biological and clinical characteristics to refine International Metastatic RCC Database Consortium (IMDC) prognostic/predictive assessment in metastatic renal cell carcinoma (mRCC).
    Zampiva, Ilaria
    Merler, Sara
    Inzerilli, Nicola
    Zacchi, Francesca
    Manduca, Stefano
    Pafumi, Sarah
    Piacentini, Michela
    Marletta, Stefano
    Incani, Ursula Cesta
    Torroni, Lorena
    Vesentini, Roberta
    Marchetti, Pierpaolo
    Fantinel, Emanuela
    Zivi, Andrea
    Calio, Anna
    Brunelli, Matteo
    Verlato, Giuseppe
    Milella, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [26] Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC)
    McKay, Rana R.
    Kroeger, Nils
    Xie, Wanling
    Lee, Jae-Lyun
    Knox, Jennifer J.
    Bjarnason, Georg A.
    MacKenzie, Mary J.
    Wood, Lori
    Srinivas, Sandy
    Vaishampayan, Ulka N.
    Rha, Sun Young
    Pal, Sumanta Kumar
    Donskov, Frede
    Tantravahi, Srinivas
    Rini, Brian I.
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [27] Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group
    Savard, Marie-France
    Wells, J. Connor
    Graham, Jeffrey
    Dudani, Shaan
    Steinharter, John A.
    McGregor, Bradley A.
    Donskov, Frede
    Bjarnason, Georg A.
    Vaishampayan, Ulka N.
    Hansen, Aaron R.
    Iafolla, Marco A. J.
    Zanotti, Giovanni
    Huynh, Lynn
    Chang, Rose
    Duh, Mei S.
    Heng, Daniel Y. C.
    ONCOLOGIST, 2020, 25 (05): : 422 - 430
  • [28] CLINICAL HETEROGENEITY AMONG FIRST-LINE SUNITINIB PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) CATEGORIZED AS INTERMEDIATE RISK (IR) GROUP ACCORDING TO THE INTERNATIONAL MRCC DATABASE CONSORTIUM (IMDC) RISK MODEL
    Huynh, L.
    Wells, J. C.
    Graham, J.
    Steinharter, J.
    McGregor, B.
    Donskov, F.
    Bjarnason, G. A.
    Vaishampayan, U.
    Hansen, A.
    Iafolla, M.
    Zanotti, G.
    Chang, R.
    Cheng, W. Y.
    Duh, M. S.
    Heng, D. Y. C.
    VALUE IN HEALTH, 2019, 22 : S59 - S60
  • [29] First-line (1L) immuno-oncology (10) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC).
    Dudani, Shaan
    Graham, Jeffrey
    Wells, Connor
    Bakouny, Ziad
    Pal, Sumanta K.
    Dizman, Nazli
    Donskov, Frede
    Porta, Camillo
    de Velasco, Guillermo
    Hansen, Aaron Richard
    Iafolla, Marco Adelmo James
    Beuselinck, Benoit
    Vaishampayan, Ulka N.
    Wood, Lori
    Liow, Elizabeth Chien Hern
    Yan, Flora
    Yuasa, Takeshi
    Bjarnason, Georg A.
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
    Gan, Chun Loo
    Dudani, Shaan
    Wells, Connor J.
    Schmidt, Andrew Lachlan
    Bakouny, Ziad
    Szabados, Bernadett
    Parnis, Francis
    Wong, Shirley
    Lee, Jae-Lyun
    de Velasco, Guillermo
    Pal, Sumanta K.
    Davis, Ian D.
    Kanesvaran, Ravindran
    Wood, Lori
    Kollmannsberger, Christian K.
    McKay, Rana R.
    Beuselinck, Benoit
    Donskov, Frede
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
12345